Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fardon, T. C.
Right arrow Articles by Lipworth, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fardon, T. C.
Right arrow Articles by Lipworth, B. J.
(Chest. 2005;127:2222-2225.)
© 2005 American College of Chest Physicians

Evaluation of an Abbreviated Adenosine Monophosphate Bronchial Challenge*

Tom C. Fardon, MA, MB Bchir; Melissa R. Hodge, BMSc and Brian J. Lipworth, MD

* From the Asthma and Allergy Research Group, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.

Correspondence to: Brian Lipworth, MD, Asthma and Allergy Research Group, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK; e-mail: b.j.lipworth{at}dundee.ac.uk

Rationale: Airway hyperresponsiveness to adenosine monophosphate (AMP) has been validated as a surrogate marker for airway inflammation. We wished to know whether an abbreviated challenge at the final threshold dose would produce the same fall in FEV1 as a full, conventional dose-response challenge.

Methods: Seventeen patients with mild-to-moderate asthma (mean FEV1, 75.5% predicted) attended for a full dose-response protocol, where the highest concentration of AMP to produce > 20% fall in FEV1 was noted, along with the maximum percentage fall and recovery time. Patients returned within 2 days for a further challenge, when they received only the highest concentration (as a single bolus) reached on the previous visit.

Results: The mean (± SEM) percentage fall in FEV1 after the full challenge was 25.5 ± 1.3%, and after the abbreviated challenge was 9.4 ± 2.4%. The mean recovery after the full challenge was 28.13 ± 4.65 min, and after the abbreviated test was 10.81 ± 4.27 min.

Conclusion: An abbreviated challenge using a single bolus dose of AMP grossly underestimates bronchial hyperresponsiveness. Although the pharmacologic half-life of AMP is short (90 s), the lesser response and shortened recovery with the abbreviated challenge suggest a more prolonged physiologic half-life, which in turn may have implications for abbreviated challenge protocols

Key Words: asthma • bronchial reactivity • pulmonary function testing






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.